Maridebart cafraglutide + Placebo
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Conditions
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Trial Timeline
Mar 17, 2025 → Apr 16, 2027
NCT ID
NCT06858878About Maridebart cafraglutide + Placebo
Maridebart cafraglutide + Placebo is a phase 3 stage product being developed by Amgen for Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight. The current trial status is active. This product is registered under clinical trial identifier NCT06858878. Target conditions include Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight.
What happened to similar drugs?
20 of 20 similar drugs in Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07441252 | Phase 2 | Recruiting |
| NCT07225686 | Phase 3 | Recruiting |
| NCT07226765 | Phase 3 | Recruiting |
| NCT07160257 | Phase 1 | Recruiting |
| NCT07037433 | Phase 3 | Recruiting |
| NCT07037459 | Phase 3 | Recruiting |
| NCT06987695 | Phase 3 | Active |
| NCT06858878 | Phase 3 | Active |
| NCT06858839 | Phase 3 | Active |
| NCT06660173 | Phase 2 | Active |
| NCT05669599 | Phase 2 | Completed |
| NCT04478708 | Phase 1 | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight